Environmental air monitoring in international airports: A novel approach for enhanced pathogen
surveillance

Dawn Gratalo[1], Cindy R. Friedman*[2], Valerie J. Morley[1], Xueting Qiu[1,4], Ian Ruskey[2], Andrew
P. Rothstein[1], Patrick B. Tiburcio[3], Casandra W. Philipson[1,4], Thomas W.S. Aichele[1,4], Stephen
M. Bart[2,4], Dustin Jaynes[5], Birgitte B. Simen[1] , Shelby L O'Connor[3], David H. O'Connor*[3]

[1] Ginkgo Biosecurity, 27 Drydock Ave 8th Floor, Boston, MA, USA

[2] Division of Global Migration Health, Centers for Disease Control and Prevention, Atlanta,
Georgia, USA

[3] Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison,
Madison, WI USA

[4] Former Affiliation

[5] Department of Public Safety, Dallas/Fort Worth International Airport, Texas, USA

Corresponding authors email: ccf6@cdc.gov and dhoconno@wisc.edu

Abstract

Early detection of outbreaks and emerging pathogens is critical for public health and global

biosecurity. Airports, as major international travel hubs with dense, enclosed populations, are

high-risk settings for disease transmission and potential pathogen introduction. The U.S. Centers

for Disease Control and Prevention, in collaboration with Ginkgo Biosecurity and the University

of Wisconsin–Madison, implemented air monitoring for pathogen surveillance in congregate

areas at four U.S. international airports. From October 2023 to August 2024, SARS-CoV-2 was

detected by PCR in 98.3% of air samples and influenza A in 17.2%. These results correlated with

positivity trends from other sample modalities, including aviation wastewater, traveler nasal

swabs, and national clinical surveillance data. Targeted amplicon sequencing of SARS-CoV-2

from air samples correlated with contemporaneous lineages in wastewater collected and

sequenced from the same airports. Metagenomic enrichment sequencing detected 30 viral species

and recovered high-quality genomes for SARS-CoV-2, influenza, bocavirus, and seasonal

coronaviruses. Together, these findings demonstrate that air sampling is a complementary

surveillance modality to aviation wastewater for early pathogen detection at ports of entry.

Key Words: Air monitoring, pathogen surveillance, airports, wastewater, SARS-CoV-2,

influenza, metagenomic sequencing, environmental surveillance, pandemic preparedness,

biosecurity

Introduction

Epidemic and pandemic preparedness relies heavily on robust and adaptive surveillance systems

capable of early pathogen detection. Global travel hubs, particularly international airports, are

critical interfaces for the introduction and spread of emerging and re-emerging pathogens due to

their dense, transient populations and high interconnectedness.[1–4] Detecting pathogens and

identifying new variants in airports is especially important, as illustrated during the COVID-19

pandemic, which underscored the urgent need for near real-time genomic surveillance

strategies.[5] While testing of nasal swabs from arriving travelers provides one modality for

monitoring, the process can be labor-intensive and relies on traveler willingness to participate.

Environmental surveillance has emerged as a non-invasive approach to characterize pathogens

circulating in communities. Wastewater surveillance, including community and aviation

wastewater, has demonstrated utility in tracking both the prevalence and genetic diversity of

viruses such as SARS-CoV-2.[6–8] Air monitoring serves as a complementary public health

surveillance tool, enabling the collection of pathogenic genetic material shed by individuals. This

approach is particularly effective for capturing respiratory pathogens from diverse populations,

including asymptomatic or pre-symptomatic individuals who might not otherwise engage with

clinical testing or contribute to accessible wastewater systems. Studies have shown the

effectiveness of air sampling in multiple congregate settings. In hospitals, airborne pathogen

detection has correlated strongly with clinical data [9], and airborne pathogen genetic material has

also been detected in other communal spaces such as schools.[10–12] As a scalable and cost-

effective surveillance option, non-invasive air monitoring is particularly relevant for high-traffic

environments, such as international airports, that serve as gateways into communities.

While PCR-based detection confirms the presence of pathogen genetic material, genomic

sequencing is essential for identifying specific lineages, tracking variant evolution, and

informing the development of diagnostics and therapeutics.[13–16] However, obtaining high-quality

genomic data from air samples presents challenges due to low biomass and nucleic acid

degradation, especially for RNA viruses.[17] Advanced sequencing methodologies are therefore

crucial. Targeted amplicon sequencing offers high sensitivity but is limited to a narrow range of

pathogens, while metagenomic approaches provide an agnostic view but often lack sensitivity for

low-abundance targets. Metagenomic enrichment sequencing represents a promising strategy to

improve both breadth and sensitivity by enriching viral nucleic acids prior to sequencing.[9,18]

In this study, air monitoring surveillance was implemented in congregate areas of four major

U.S. international airports to assess the feasibility of detection of SARS-CoV-2 and Influenza A

virus genetic material in an international airport setting; evaluate the effectiveness of sequencing

methods for viral genome characterization from these air samples; and determine the

complementary value of air monitoring within existing pathogen surveillance frameworks. This

study explores the development of air monitoring as a proactive biosecurity system, to enhance

our capacity for early threat identification at the critical intersection of global travel and

community health.

Methods

ThermoFisher AerosolSense™ active air samplers were placed in congregate areas adjacent to

customs and immigration inspection areas and within proximity of several hundred arriving

international passengers at San Francisco International Airport, California (SFO); Newark

Liberty International Airport, New Jersey (EWR); Washington Dulles International Airport,

Virginia (IAD); and Dallas/Fort Worth International Airport, Texas (DFW). Samplers were

placed on tables 28-30 inches above the ground. The ThermoFisher AerosolSense™ has a built-

in pump, that operates at 200 liters per minute, and a proprietary sample collection cartridge.

Each ThermoFisher AerosolSense™ unit collected samples for 10 hours per day. ThermoFisher

AerosolSense™ cartridges containing polyurethane foam substrates were removed from each air

sampling machine after approximately 20 hours of use Monday through Thursday and after 30

hours of use Friday through Sunday.

Samples were collected from October 18, 2023–August 27, 2024, at SFO, EWR, and IAD, and

from February 7–August 14, 2024, at DFW. At SFO, a second sampler was added on June 3,

2024 (denoted by the orange star in Figure 1), and both instruments operated until study end.

Cartridges were packaged and shipped   at room temperature to UW-Madison for extraction and

qRT-PCR analyses. All results were linked to airport and collection date via unique barcodes.

Each substrate was submerged in 500 µL of 1X phosphate-buffered saline (PBS) and vortexed.

RNA was extracted from 300 µL of eluate using a Maxwell® RSC Viral Total Nucleic Acid

Purification Kit (Promega). Molecular detection of SARS-CoV-2, influenza A, and RNase P is

described in Supplemental Methods. From October 18, 2023–March 12, 2024, qRT-PCR

reactions were performed on a LightCycler® 480 System (Roche) using a TaqMan Fast Virus 1-

Step Kit (ThermoFisher) with CDC-modified assays targeting the SARS-CoV-2 nucleocapsid

gene (N1, N2) and the influenza A M gene, in duplicate.[19] Pathogen results were categorized as

positive if both Ct values were <40, inconclusive if only one Ct <40, and negative if neither Ct

<40. This categorization applied to both SARS-CoV-2 and influenza A assays. On March 12,

2024, the thermocycler was changed to accommodate a multiplex assay (denoted by the red star

in Figure 1). For each cartridge, a single multiplex assay measuring the SARS-CoV-2 N1 and

influenza A M targets were performed. The human RNase P gene served as an internal control;

samples negative for RNase P were excluded from analysis.

For targeted SARS-CoV-2 sequencing, purified total nucleic acid (TNA) was amplified by

multiplex RT-PCR (NEB LunaScript Multiplex One-Step RT-PCR) using the ARTIC primer set

(IDT ARTIC V5.3.2 NCOV-2019 Panel).[20] Amplicons were pooled, and libraries prepared with

a modified Illumina DNA Prep protocol. Libraries were sequenced on an Illumina NovaSeq

6000, targeting ~1.5 million paired-end 150 bp reads per sample.

For metagenomic enrichment sequencing, input to library prep was either total nucleic acid

(TNA) or clean and concentrated TNA (Zymo Research, Irvine, CA). Extracts were prepared for

enrichment using the Illumina RNA for Enrichment Sample Preparation Kit with the Respiratory

Virus Oligo Panel, following the manufacturer's protocol (Illumina, San Diego, CA). Libraries

were validated for size and adapter dimer removal on an Agilent TapeStation 4200 D1000 High

Sensitivity assay, quantified and normalized using the dsDNA High Sensitivity Assay on a Qubit

3.0 (Life Technologies, Carlsbad, CA), denatured/diluted, and pooled per manufacturer's

instructions. Pooled libraries were sequenced on the Illumina NovaSeq 6000 (v1.5 chemistry) to

a target depth of ~7 million paired-end 150 bp reads per sample. Bioinformatics pipelines and

analysis details are provided in Supplemental Data.

For aviation wastewater and traveler nasal swabs, data were generated from samples collected

and processed as part of the [Traveler Genomic Surveillance (TGS) program](#) from October 18th,

2023-August 27th, 2024. Aviation wastewater was collected from arriving international airplanes

at IAD (N=330), and SFO wastewater was collected from triturators (N=161).Triturators are

collection points where waste from multiple flights is discharged and homogenized before being

combined with airport terminal wastewater. Travelers volunteered to self-collect anterior nasal

swabs on arrival at IAD (N = 16,004) and SFO (N = 30,182). Wastewater samples were

concentrated with Nanotrap Microbiome Particles and extracted using a MagMAX Microbiome

Ultra Nucleic Acid Isolation Kit (Thermo Fisher). Extracts were tested by digital PCR for SARS-

CoV-2 and influenza A/B (Qiagen), and SARS-CoV-2 sequencing was performed as described

above.

Upon laboratory receipt, nasal swab samples were heat-inactivated at 70°C for 30 minutes, and

total nucleic acids extracted using the MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit

(Thermo Fisher). Extracts were tested by qPCR using the TrueMark™ SARS-CoV-2/Flu A/Flu

B/RSV Select Panel on a QuantStudio™ 5 qPCR instrument (Thermo Fisher). SARS-CoV-2

sequencing was performed as described above.

This activity was reviewed by CDC, deemed not human subjects research, and conducted in

accordance with applicable federal law and CDC policy (45 CFR part 46; 21 CFR part 56).

Results

During October 18, 2023–August 27, 2024, 463 air monitoring samples were collected and tested by qRT-PCR from four international airports (Figure 1). The RNase P control was positive for 460 of 463 samples (99.1%). Among these 460 RNAseP+ samples, SARS-CoV-2 was detected in 452 (98.3%). Of the remaining eight samples, five were negative and three were inconclusive. When stratified by airport, positive SARS-CoV-2 detections were: SFO: 137 (97.9%), EWR: 124 (98.4%), IAD: 118 (97.5%), and DFW: 73 (100%) (Figure 1).

Among the 460 RNAseP+ samples, 79 were positive for influenza A (17.2%), while 327 were negative and 54 were inconclusive. By airport, influenza A detections were: SFO: 36 (25.7%), EWR: 20 (15.9%), IAD: 10 (8.3%), and DFW: 13 (17.8%). Positive detections of influenza A occurred weekly between January 1 and March 18, 2024, then occurred sporadically through April 22, 2024, after which no further positives were observed (Figure 1).

To compare SARS-CoV-2 and influenza A trends across modalities, data from two airports (SFO and IAD) with overlapping aviation wastewater, airport air, and traveler nasal swab collections were analyzed. Publicly available U.S. clinical respiratory specimen data (https://www.cdc.gov/nrevss/php/dashboard/index.html) were also included for comparison. Airport air and aviation wastewater had higher weekly positivity rates for SARS-CoV-2 and influenza A than traveler nasal swabs and national clinical samples, reflecting expected differences between population-level (air, wastewater) and individual-level (nasal swab) sampling (Figure 2A). SARS-CoV-2 PCR values from air sampling correlated significantly with aviation wastewater (Figure 2B; Pearson's $p < 0.001$), but not with percent positivity in traveler nasal swabs (Figure 2C; $p = 0.24$), and national surveillance (Figure 2D; $p = 0.13$). Influenza A

positivity from air sampling correlated significantly with aviation wastewater (Figure 2E; p =

0.002), traveler nasal swabs (Figure 2F; p < 0.001), and national surveillance (Figure 2G; p <

0.001).

Of the 460 RNAseP+ air samples, 338 were tested for SARS-CoV-2 sequences; 216 (64%)

yielded high-quality genomes (≥70% genome coverage), and 167 (77%) of those contained

multiple lineages including BA.2.86, JN.1, JN.1.16, JN.1.67, KP.1, KP.2, KP.3, KP.3.1.1, and

XDV. SARS-CoV-2 variant trends in air and aviation wastewater samples were similar at both

airports (Figure 3A, 3B). Between January 29 and August 26, 2024, both sample types showed a

decline in Omicron JN.1 and an increase in KP.2/KP.3, consistent with contemporaneous

national trends.[21] KP.x variants were detected in aviation wastewater earlier than air samples (42

days earlier for KP.2, 41 days earlier for KP.3).

Metagenomic sequencing with hybrid capture enrichment for respiratory virus genomes was

performed on a total of 98 air samples, split into two sequencing runs (Figure 4), using samples

that did not overlap with those used for SARS-CoV-2 amplicon sequencing. In the first run

(N=52), a mean of 0.04% (95% CI [0.01%, 0.06%]) of total reads per sample mapped to virus

targets. After incorporating a TNA concentration step prior to library prep, the second run (N =

46) achieved a mean of 11.8% (95% CI: 7.04 –16.5%) of reads mapping to viral genomes.

Across all samples, reads from 30 viral species were detected. The most frequent were SARS-

CoV-2 (100% of samples; mean RPKM 1007, 95% CI: 351-1663), influenza A (57% of samples;

mean RPKM 111, 95% CI: 62.7-159), and seasonal coronavirus HCoV-229E (45% of samples;

mean RPKM 163, 95% CI: 18.9-306). Influenza B (28%), RSV A (29%), and RSV B (43%)

were also detected. For influenza A, 88% (28/32) of PCR-positive samples had sequencing reads

mapping to the genome. An additional 27 samples with influenza A reads were PCR-

inconclusive (n = 12) or negative (n = 15).

In addition to revealing viral diversity, enrichment sequencing yielded high-quality genomes

(≥70% reference coverage at 10× depth) in 4% (2/52) of samples from the first run and 35%

(16/46) of samples from the optimized second run. Overall, 25 high-quality genomes were

recovered from 98 samples, including SARS-CoV-2 (n = 11), influenza A (n = 4), bocavirus (n =

2), WU polyomavirus (n = 5), and seasonal coronaviruses (n = 3).

Discussion

The findings of this project support air sampling as a viable option for pathogen surveillance in

airports. The data suggests that i) air sampling can serve as a layered or alternative surveillance

option, ii) targeted genomic sequencing from air samples provides the resolution needed to

identify important variants, and iii) metagenomic enrichment sequencing enables multipathogen

detection from air. To our knowledge, this is the first study to demonstrate a correlation between

respiratory viruses detected in air samples, aviation wastewater, and nasal swabs from travelers

at the same airport, as well as with national clinical respiratory data. Both air and wastewater

monitoring offer valuable insights. The strong correlation in observed trends across these two

systems underscores their complementary value in a multi-layered surveillance approach, with

each capturing signals from distinct yet overlapping populations.

In airport environments, air monitoring offers real-time, surveillance, serving as a crucial

interface between emerging threats and community spread. In this project SARS-CoV-2 RNA

was detected in nearly all samples (98.3%) compared with 17.2% for influenza A. Influenza A

detections were concentrated in the winter months and mirrored national clinical data trends

from the 2023-2024 influenza season. The near ubiquitous detection of SARS-CoV-2

underscores the value of genomic sequencing for tracking new variant introductions of highly

prevalent pathogens. Sequencing in our study showed JN.1 as the predominant lineage, followed

by increases in KP.2 and KP.3 sublineages, consistent with national surveillance data.[21] In this

study, KP.2 and KP.3 lineages were detected substantially earlier in aviation wastewater than in

air samples. However early detection was found to be dependent on the sample type when

comparing airplane (IAD) and triturator (SFO) wastewater individually against air samples

(Supplemental Fig). While some KP.x signals appeared earlier in air than triturator wastewater at

specific time points, a controlled comparison across all modalities at the same airport and time

would be required to determine whether this reflects true early detection or variation related to

low-abundance airborne material.

Genomic sequencing of air sampling has been shown as a highly effective method for pathogen

surveillance,[11,12,22]but methodological considerations remain. Targeted amplicon methods,

commonly applied to SARS-CoV-2, have excellent sensitivity, which is valuable for identifying

circulating lineages, but interrogate only a narrow set of pathogens. Untargeted metagenomic

sequencing captures a broader diversity of pathogens; but the low amount of starting genomic

material in air samples presents a technical challenge. Here, we addressed this challenge with

hybrid-capture enrichment sequencing, enabling detection of a broad panel of pathogens despite

the limitations of input material. Our results show that metagenomic enrichment sequencing

increased mapped reads and improved recovery of high-quality genomes from air samples. This

approach also detected more influenza A material than PCR, though this may reflect limitations

of the specific PCR assay (suggested by the number of inconclusive results) as well as the low

sequencing thresholds applied in our study (any read counted as detection).

Our study identified several limitations. First, variations in viral genome reference coverage, due

to differing numbers of reads and depth of coverage, may have impacted lineage assignment,

particularly in low-biomass air samples. Second, operational constraints meant sampling duration

and cartridge change timing were not fully standardized. However, we believe these modest

variations did not materially alter the overall findings. Finally, minor temporal uncertainty in

signal attribution may have been introduced by the imprecise placement and removal times of the

cartridges.

Future research should prioritize enhancing sensitivity by improving air sample collection,

nucleic acid recovery, and sequencing efficiency to better detect less abundant pathogens. A

parallel focus should be on defining clear detection limits, which will strengthen confidence in

genomic data, especially when only limited genomic sequences are recovered.

More broadly, air monitoring technologies currently face technical and operational limitations

that require further research and development. Before these systems are widely deployed for

biosurveillance, their limits of detection, quantification, and optimal sampling time for pathogens

of interest must be rigorously characterized under realistic environmental conditions. In addition,

a better understanding of how airflow dynamics, building design, and population density

influence sampling efficiency and detection probability would substantially enhance the

capability and reliability of these technologies.

Beyond technical considerations, the operational readiness of air monitoring for routine public

health use depends on policy, ethical, and implementation factors. These include data

interpretability for decision-making, coordination with airport authorities and industry partners,

governance around data use, and clear triggers for public health response. As with other

environmental surveillance systems, air monitoring is most effective when integrated into

established surveillance frameworks rather than deployed as a standalone tool.

Unlike airplane wastewater and traveler nasal swab sampling, which are directly linked to

arriving international passengers, air sampling in airport terminals lacks a clear demographic or

epidemiological boundary. Air collected in congregate terminal spaces reflects a mixed

population that can include airport staff, domestic travelers, and members of the surrounding

community, introducing uncertainty regarding attribution to inbound international travel. This

limitation reduces the specificity of air sampling for monitoring pathogen importation and must

be considered when interpreting variant origin or timing signals relative to other aviation-based

surveillance modalities. However, air sampling can provide a complementary layer within a

multi-modality framework. Its primary value lies in continuous detection of respiratory

pathogens within high-risk indoor environments, capturing signals from individuals who may not

contribute to wastewater or participate in voluntary nasal sampling. While air monitoring did not

demonstrate earlier lineage detection in all aviation wastewater types in this study, it may offer

situational awareness, confirmation of ongoing transmission, and persistence signals during

outbreak onset or decline, particularly when other data streams are delayed, unavailable, or

operationally constrained.

Air monitoring provides a non-invasive means to track pathogen presence and spread in specific

environments. It complements clinical surveillance by capturing signals from large numbers of

asymptomatic or mildly symptomatic individuals who would otherwise go undetected. By

offering insights into pathogen dynamics, air monitoring can support early threat detection and

enable timely public health interventions, even before clinical cases are widely reported. It has

been applied in schools[12] and proposed for long-term care facilities and workplace settings. Air

monitoring may also be particularly valuable where wastewater surveillance is impractical, such

as in maritime environments, where access to wastewater is limited and where dense

populations, close contact, and frequent embarkation/disembarkation increase both transmission

risk and the potential for pathogen introduction.[23]

In the future, indoor air detection of viral pathogens in airports or other international ports of

entry could become a cornerstone of proactive pandemic preparedness. Continuous or

intermittent air sampling, coupled with rapid detection technologies, could provide real-time

insights into circulating pathogens. Upon detection of elevated viral loads, targeted mitigation

measures, such as increased ventilation[24], air purification[25], public health messaging, or resource

allocation, could be swiftly launched. This proactive approach, moving beyond reactive clinical

case identification, could significantly reduce the risk of disease spread and enhance global

health security. Our study highlights air sampling as a feasible, non-invasive strategy for

pathogen surveillance. Integrating airport air sampling into existing frameworks can enhance the

ability to identify emerging threats and build more resilient, proactive biosecurity systems to

address current and future challenges.

Declaration of Competing Interests

to D.H.O. from the Wisconsin Department of Health Services (435100-A24-ELCProjE) and the

US Centers for Disease Control and Prevention (75D30122C15355). D.H.O. and S.L.O. are

managing partners of Pathogenuity LLC, a consultancy that advises on environmental

monitoring issues. S.L.O.'s work on this project was funded by Inkfish and Heart of Racing.

The funders played no role in the drafting of this manuscript. The authors are not aware of any

affiliations, memberships, funding, or financial holdings that might be perceived as affecting the

objectivity of this manuscript.

The findings and conclusions in this report are those of the author(s) and do not necessarily

represent the official position of the Centers for Disease Control and Prevention/the Agency for

Toxic Substances and Disease Registry.

Author contributions

DG, CRF, SLO, and DHO contributed to ideas, work, writing, accountability and stewardship.

CWP contributed to ideas, work, and stewardship. AR and VJM contributed to work, writing and

accountability. BBS contributed to writing, accountability, and stewardship. XQ and PBT

contributed to work. TWSA contributed to ideas and work. SB and DJ contributed to work. IR

contributed to ideas and accountability.

Acknowledgements

We are deeply grateful to our partners at XpresCheck for sample collection and support. We

thank Amy Schierhorn for program support. We thank Bo Reese and staff at Center for Genome

Innovation, Institute for Systems Genomics, University of Connecticut for sequencing support.

We thank the CDC Port Health Station staff including Steve Burchell, Erica Sison, Jonathan

Georges, Helen MacGregor, Kara Adams, and Ayianna Kennerly. We also thank Miranda Stauss

and Eli O'Connor in the O'Connor Labs for cartridge tracking.

Data Availability

All raw sequencing data is available in the NCBI sequence read archive (SRA) database under

CDC's Traveler-Based Genomic Surveillance Program BioProject PRJNA989177. All other code

used to generate figures is available at https://github.com/concentricbyginkgo/TGS-

AirMonitoring-Supplemental.

References

1.   Tegally, H. *et al.* Dispersal patterns and influence of air travel during the global
expansion of SARS-CoV-2 variants of concern. *Cell* **186**, 3277-3290.e16 (2023).

2.   Baker, R. E. *et al.* Infectious disease in an era of global change. *Nat Rev Microbiol* **20**,
193–205 (2022).

3.   Mangili, A. & Gendreau, M. A. Transmission of infectious diseases during commercial
air travel. *The Lancet* **365**, 989–996 (2005).

4.   Wilder-Smith, A. COVID-19 in comparison with other emerging viral diseases: risk of
geographic spread via travel. *Trop Dis Travel Med Vaccines* **7**, 3 (2021).

5.   Wegrzyn, R. D. *et al.* Early Detection of Severe Acute Respiratory Syndrome
Coronavirus 2 Variants Using Traveler-based Genomic Surveillance at 4 US Airports, September
2021–January 2022. *Clin Infect Dis* **76**, e540–e543 (2023).

6.   Ahmed, W. *et al.* Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in
aircraft wastewater. *Science of The Total Environment* **820**, 153171 (2022).

7.   Morfino, R. C. Notes from the Field: Aircraft Wastewater Surveillance for Early
Detection of SARS-CoV-2 Variants — John F. Kennedy International Airport, New York City,
August–September 2022. *MMWR Morb Mortal Wkly Rep* **72**, (2023).

8.   Agrawal, S. *et al.* Genome Sequencing of Wastewater Confirms the Arrival of the SARS-
CoV-2 Omicron Variant at Frankfurt Airport but Limited Spread in the City of Frankfurt,
Germany, in November 2021. *Microbiology Resource Announcements* **11**, e01229-21 (2022).

9.   Bobrovska, S. *et al.* Hospital air sampling enables surveillance of respiratory virus
infections and genomes. *Science of The Total Environment* **977**, 179346 (2025).

10.   Minor, N. R. *et al.* Metagenomic sequencing detects human respiratory and enteric
viruses in air samples collected from congregate settings. *Scientific Reports* **13**, 21398 (2023).

11.   Ramuta, M. D. *et al.* SARS-CoV-2 and other respiratory pathogens are detected in
continuous air samples from congregate settings. *Nat Commun* **13**, 4717 (2022).

12.   Temte, J. *et al.* Four Methods for Monitoring SARS-CoV-2 and Influenza A Virus
Activity in Schools. *JAMA Netw Open* **6**, e2346329 (2023).

13.   Houldcroft, C. J., Beale, M. A. & Breuer, J. Clinical and biological insights from viral
genome sequencing. *Nat Rev Microbiol* **15**, 183–192 (2017).

14.   Hilt, E. E. & Ferrieri, P. Next Generation and Other Sequencing Technologies in
Diagnostic Microbiology and Infectious Diseases. *Genes* **13**, 1566 (2022).

15.   Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and challenges
in virus genomic epidemiology. *Trends in Parasitology* **37**, 1038–1049 (2021).

16.   Quainoo, S. *et al.* Correction for Quainoo et al., "Whole-Genome Sequencing of
Bacterial Pathogens: the Future of Nosocomial Outbreak Analysis". *Clinical Microbiology*
Reviews **31**, 10.1128/cmr.00082-17 (2017).

17.   Behzad, H., Gojobori, T. & Mineta, K. Challenges and Opportunities of Airborne
Metagenomics. *Genome Biology and Evolution* **7**, 1216–1226 (2015).

18.   Quek, Z. B. R. & Ng, S. H. Hybrid-Capture Target Enrichment in Human Pathogens:
Identification, Evolution, Biosurveillance, and Genomic Epidemiology. *Pathogens* **13**, 275
(2024).

19.   Lu, X. *et al.* US CDC Real-Time Reverse Transcription PCR Panel for Detection of
Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 8—August 2020 -
Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2608.201246.

20.   Quick, J. nCoV-2019 sequencing protocol. (2020).

21.   Ma, K. C. *et al.* Genomic Surveillance for SARS-CoV-2 Variants: Circulation of
Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024. *MMWR Morb*
Mortal Wkly Rep **73**, 938–945 (2024).

22.   Raymenants, J. *et al.* Indoor air surveillance and factors associated with respiratory
pathogen detection in community settings in Belgium. *Nat Commun* **14**, 1332 (2023).

23.   Kumar, P. *et al.* Airborne pathogen monitoring and dispersion modelling on passenger
ships: A review. *Science of The Total Environment* **980**, 179571 (2025).

24.   Faulkner, C. A. *et al.* Comparison of effectiveness and energy use of airborne pathogen
mitigation measures to meet clean air targets in a prototypical office building. *Building and*
Environment **257**, 111466 (2024).

25.   Azimi, P. & Stephens, B. HVAC filtration for controlling infectious airborne disease
transmission in indoor environments: Predicting risk reductions and operational costs. *Build*
Environ **70**, 150–160 (2013).

Figure 1: PCR detection from airport air samples. Positive qRT-PCR detections and Ct values of Influenza A, SARS-CoV-2, and RNase P controls captured by ambient air monitoring surveillance from congregate areas in 4 U.S. international airports, October 2023–August 2024. The red star indicates a change of assay; quantitative results before and after this point cannot be directly compared. The orange star indicates when a second sampler was added to the San Francisco airport.

Figure 2: Respiratory virus positivity trends for airport air, aviation wastewater, and

traveler nasal swab surveillance. As part of the CDC TGS program, two international airports

(SFO and IAD) had overlapping collections for aviation wastewater, airport air, and individual

traveler nasal swabs from October 18, 2023-August 27, 2024. Data from these two airports were

used to compare virus positivity trends across surveillance modalities. Publicly available data

from USA respiratory virus clinical testing (CDC NREVSS) was also included for comparison to

national trends. A) Percent positivity for influenza A and SARS-CoV-2 PCR detection compared

across surveillance modalities. B-D) Correlation between airport air PCR values for SARS-CoV-

2 and (B) aviation wastewater PCR values, (C) traveler nasal percent PCR positivity, and (D)

NREVSS clinical percent positivity. Because percent positivity was near 100% for SARS-CoV-2

in airport air and aviation wastewater samples, PCR values (copies/mL wastewater or

copies/substrate for air) were analyzed instead of percent positivity. E-G) Correlation between

airport air weekly percent positivity for influenza A and (E) aviation wastewater percent

positivity, (F) traveler nasal swab percent positivity, and (G) NREVSS clinical percent positivity.

Figure 3a, b: SARS-CoV-2 genomes from wastewater and air samples at two airports (SFO and IAD), samples collected from Jan 29, 2024 to Aug 26, 2024. Genomic sequencing data from **A.** aviation wastewater (SFO-triturator, IAD-airplane) and **B.** Air samples. Aviation wastewater includes both triturator (aggregate airplane lavatory waste) from SFO, and airplane wastewater (individual flight lavatory waste) from IAD.

Figure 4: Detection of viral genomes from air samples by metagenomic enrichment

sequencing. Nucleic acid extracted from air filters (N=98) collected from three airports (EWR,

IAD, SFO) was sequenced using the Illumina Respiratory Viral Oligo hybrid-capture panel for

respiratory viruses. Samples to the right of the red line indicate when an RNA concentration step

was added to the sequencing library prep protocol. The heatmap shows the normalized

abundance of reads mapping to each viral target (RPKM = reads per kilobase per million reads).

420